Literature DB >> 8866952

GR 127935 blocks the locomotor and antidepressant-like effects of RU 24969 and the action of antidepressants in the mouse tail suspension test.

M F O'Neill1, A G Fernández, J M Palacios.   

Abstract

The 5-HT1A/B agonist RU 24969 induces hyperactivity in rodents and also shows antidepressant-like effects in some animal models of depression. We have examined the effects of selective antagonists at 5-HT1A and 5-HT1B/D receptors (WAY 100135 and GR 127935, respectively) on both the hyperlocomotor and anti-immobility effects of RU 24969. While a high dose of WAY 100135 (10 mg/kg) had no effect in either paradigm, GR 127935 attenuated the behavioural effects of RU 24969 in both. WAY 100135 was also without effect on the antidepressant effect of paroxetine, while GR 127935 blocked the effects of paroxetine (1 mg/kg) and imipramine (10 mg/kg). Furthermore, while coadministration of paroxetine or imipramine enhanced the effects of RU 24969 in the mouse tail suspension test, imipramine had no effect on the locomotor activating effects of the 5-HT1B agonist, suggesting different neural substrates may underly the effects in the different tests. These studies indicate a role for the 5-HT1B/D receptor in the mediation of the effects of antidepressant treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866952     DOI: 10.1016/0091-3057(95)02047-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

1.  The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent.

Authors:  Agnieszka Pałucha-Poniewiera; Piotr Brański; Joanna M Wierońska; Katarzyna Stachowicz; Anna Sławińska; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2014-01       Impact factor: 4.530

2.  Glycogen synthase kinase-3β is a functional modulator of serotonin-1B receptors.

Authors:  L Chen; W Zhou; P C Chen; I Gaisina; S Yang; X Li
Journal:  Mol Pharmacol       Date:  2011-03-03       Impact factor: 4.436

3.  Paroxetine-induced reduction of sexual incentive motivation in female rats is not modified by 5-HT1B or 5-HT2C antagonists.

Authors:  Helge Kaspersen; Anders Agmo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-10       Impact factor: 4.530

4.  NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test.

Authors:  Mehdi Ghasemi; Laleh Montaser-Kouhsari; Hamed Shafaroodi; Behtash Ghazi Nezami; Farzad Ebrahimi; Ahmad Reza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2009-07-16       Impact factor: 4.530

5.  Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.

Authors:  Mark J Millan; Sylvie Veiga; Sylvie Girardon; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

6.  Direct and indirect 5-HT receptor agonists produce gender-specific effects on locomotor and vertical activities in C57 BL/6J mice.

Authors:  Bethany R Brookshire; Sara R Jones
Journal:  Pharmacol Biochem Behav       Date:  2009-08-19       Impact factor: 3.533

Review 7.  Role of 5-hydroxytryptamine 1B (5-HT1B) receptors in the regulation of ethanol intake in rodents.

Authors:  Youssef Sari
Journal:  J Psychopharmacol       Date:  2012-10-31       Impact factor: 4.153

8.  The effects of glycogen synthase kinase-3beta in serotonin neurons.

Authors:  Wenjun Zhou; Ligong Chen; Jodi Paul; Sufen Yang; Fuzeng Li; Karen Sampson; Jim R Woodgett; Jean Martin Beaulieu; Karen L Gamble; Xiaohua Li
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

Review 9.  The 5-HT1B receptor - a potential target for antidepressant treatment.

Authors:  Mikael Tiger; Katarina Varnäs; Yoshiro Okubo; Johan Lundberg
Journal:  Psychopharmacology (Berl)       Date:  2018-03-15       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.